NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Takeda Pharmaceutical Company Limited (TAK) Stock Analysis

Takeda Pharmaceutical Company Limited (TAK) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

TAK

$18.45

−$0.26 (−1.39%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TAK with… →

TAK Key Statistics

As of Sep 4, 2026
Trading
Open
$18.48
Previous Close
$18.71
Day's Range
18.39–18.54
52-Week Range
12.99–18.90
Volume
1.50M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.10
Valuation
Market Cap
$58.92B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
34.81
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.43
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.33
Financials (FY)
Revenue (FY)
$4.51T−1.66%
Net Income (FY)
−$152.39B−241.20%
Profit marginThe share of revenue left as profit after all costs and taxes.
−3.54%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.19B
1-Year Return
+20.67%
Dividend and dates
Dividend
$0.62+3.34%
Ex-Dividend Date
March 31, 2026
Earnings Date
October 29, 2026
Avg Volume
3.20M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TAK Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+18.35%
2025+20.46%
2024−3.12%
2023−8.53%
2022+14.45%
2021−25.11%
2020−7.75%
2019+17.30%
2018−40.88%
2017+36.91%
2016 (partial year)−10.78%

As of September 4, 2026.

TAK Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$4.51T−$152.39B−3.4%
2024$4.58T$107.93B2.4%
2023$4.26T$144.07B3.4%
2022$4.03T$317.02B7.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.51T$2.93T$464.45B−$152.39B−3.4%
2024$4.58T$3.00T$466.37B$107.93B2.4%
2023$4.26T$2.84T$309.90B$144.07B3.4%
2022$4.03T$2.78T$587.81B$317.02B7.9%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

TAK Dividend History

$0.34−45.1% vs 2024

Dividends per share, 2025 · 1 payments

YearDividends per sharePaymentsChange
2025$0.341−45.1%
2024$0.622—

Most recent payment: $0.34 per share, ex-dividend March 31, 2025. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

TAK Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricTAKDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.012.300.0x the median
Profit margin−3.54%−3.14%0.4 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Takeda Pharmaceutical Company Limited (TAK) is capitalised at $58.92B on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 47,029 employees.

The most recent close on file for TAK is $18.45, dated September 4, 2026. That is −$0.26 (−1.39%) against the previous close. The 52-week range on file runs from $12.99 to $18.90. The latest close sits 42.03% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $4.51T. Against the prior fiscal year total of $4.58T, that is a change of −1.66%. The same year closed with a net loss of $152.39B. The reported profit margin is −3.54%. That is 0.4 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.33.

Across the 4 fiscal years on file, revenue moves from $4.03T in 2022 to $4.51T in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 34.81. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.43.

The reported beta is 0.1. Annualized volatility over the trailing 10 years is 23.13%. Over the trailing twelve months the price has returned +20.67%. Across 10 years the annualized return works out at −1.50%.

Growth & Income

The trailing dividend yield is 3.34%. That is 1.3 percentage points above the Drug Manufacturers - Specialty & Generic median yield of 2.06%. The indicated annual rate is $0.62 a share. The ex-dividend date on file is March 31, 2026. Dividends are recorded for 2 calendar years; 2025 shows 1 payments totalling $0.34 a share. The year before, 2024, totalled $0.62 a share.

The strongest complete calendar year on file is 2017 at +36.91%; the weakest is 2018 at −40.88%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the price is +18.35%.

Peer Comparison

Takeda Pharmaceutical Company Limited (TAK) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0
Zoetis Inc. ZTS $31.33B 12.4

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Takeda Pharmaceutical Company Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B

 NBIX

Neurocrine Biosciences, Inc.

$15.82B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Visit website →